XML 37 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Business Segment Information
12 Months Ended
Dec. 31, 2020
Business Segment Information  
Business Segment Information

12. Business Segment Information

The accounting policies of the Company’s segments are the same as those described in Note 2—“Summary of Significant Accounting Policies.” The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest and other income, changes in the fair value of contingent consideration recorded in relation to acquisitions, gain on sale of assets, special charges or benefits, and income taxes (“Segment Profit”). Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Healthcare subcontracts with Pharmacy Management to provide pharmacy benefits management services for certain of Healthcare’s customers. In addition, Pharmacy Management provides pharmacy benefits management for the Company’s employees covered under its medical plan. As such, revenue, cost of goods sold and direct service costs and other related to these arrangements are eliminated. The Company’s segments are defined in Note 1—“General.”

The following tables summarize, for the periods indicated, operating results by business segment for the years ended December 31, 2018, 2019 and 2020 (in thousands):

    

    

    

Corporate

    

 

Pharmacy

and

 

    

Healthcare

    

Management

    

Elimination

    

Consolidated

 

Year Ended December 31, 2018

Managed care and other revenue

$

2,110,756

$

240,427

$

(607)

$

2,350,576

PBM and dispensing revenue

 

 

2,625,417

 

(18,471)

 

2,606,946

Cost of care

 

(1,554,691)

 

 

 

(1,554,691)

Cost of goods sold

 

 

(2,468,170)

 

15,467

 

(2,452,703)

Direct service costs and other

 

(401,083)

 

(298,713)

 

(74,119)

 

(773,915)

Stock compensation expense (1)

6,446

5,458

17,032

28,936

Changes in fair value of contingent consideration (1)

1,108

1,108

Segment profit (loss)

$

162,536

$

104,419

$

(60,698)

$

206,257

Identifiable assets by business segment (2)

Restricted cash

$

52,681

$

576

$

2,954

$

56,211

Net accounts receivable

 

192,239

 

465,345

 

150

 

657,734

Investments

 

91,841

 

7,037

 

 

98,878

Pharmaceutical inventory

 

 

40,818

 

 

40,818

Goodwill

 

410,869

 

395,552

 

 

806,421

Other intangible assets, net

 

32,893

 

82,072

 

13,167

 

128,132

    

    

    

Corporate

    

 

Pharmacy

and

 

    

Healthcare

    

Management

    

Elimination

    

Consolidated

 

Year Ended December 31, 2019

Managed care and other revenue

$

2,082,088

$

265,439

$

(592)

$

2,346,935

PBM revenue

 

 

2,236,829

 

(18,151)

 

2,218,678

Cost of care

 

(1,543,524)

 

 

 

(1,543,524)

Cost of goods sold

 

 

(2,076,509)

 

17,224

 

(2,059,285)

Direct service costs and other

 

(402,006)

 

(323,162)

 

(76,499)

 

(801,667)

Stock compensation expense (1)

 

7,639

 

7,834

 

9,200

 

24,673

Segment Profit (Loss)

$

144,197

$

110,431

$

(68,818)

$

185,810

Identifiable assets by business segment (2)

Restricted cash

$

49,027

$

2,226

$

$

51,253

Net accounts receivable

 

201,462

 

478,627

 

480

 

680,569

Investments

 

94,943

 

6,718

 

 

101,661

Pharmaceutical inventory

 

 

44,962

 

 

44,962

Goodwill

 

410,869

 

395,552

 

 

806,421

Other intangible assets, net

 

20,059

 

61,536

 

80

 

81,675

    

    

    

Corporate

    

 

Pharmacy

and

 

    

Healthcare

    

Management

    

Elimination

    

Consolidated

 

Year Ended December 31, 2020

Managed care and other revenue

$

1,959,869

$

290,855

$

(703)

$

2,250,021

PBM revenue

 

 

2,347,446

 

(19,936)

 

2,327,510

Cost of care

 

(1,397,855)

 

 

 

(1,397,855)

Cost of goods sold

 

 

(2,199,674)

 

18,957

 

(2,180,717)

Direct service costs and other

 

(433,723)

 

(360,970)

 

(85,475)

 

(880,168)

Stock compensation expense (1)

 

6,876

 

7,723

 

10,573

 

25,172

Segment Profit (Loss)

$

135,167

$

85,380

$

(76,584)

$

143,963

Identifiable assets by business segment (2)

Restricted cash

$

33,381

$

12,658

$

3,188

$

49,227

Net accounts receivable

 

229,250

 

509,086

 

5,166

 

743,502

Investments

 

136,243

 

7,216

 

 

143,459

Pharmaceutical inventory

 

 

43,334

 

 

43,334

Goodwill

 

478,227

 

395,552

 

 

873,779

Other intangible assets, net

 

39,446

 

40,243

 

 

79,689

(1)Stock compensation expense, changes in the fair value of contingent consideration recorded in relation to the acquisitions and impairment of intangible assets are included in direct service costs and other operating expenses; however, these amounts are excluded from the computation of Segment Profit.
(2)Identifiable assets by business segment are those assets that are used in the operations of each segment. The remainder of the Company’s assets cannot be specifically identified by segment.

The following table reconciles consolidated income before income taxes to Segment Profit for the years ended December 31, 2018, 2019 and 2020 (in thousands):

2018

    

2019

    

2020

Income (loss) from continuing operations before income taxes

$

33,633

$

21,759

$

(40,485)

Stock compensation expense

 

28,936

 

24,673

 

25,172

Changes in fair value of contingent consideration

1,108

Depreciation and amortization

 

112,284

 

110,367

 

98,387

Interest expense

 

35,180

 

35,868

 

30,865

Interest and other income

 

(4,884)

 

(6,857)

 

(4,054)

Special charges

34,078

Segment Profit from continuing operations

$

206,257

$

185,810

$

143,963